

Accepted Manuscript

Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma

Abigail E. Kaye , Elizabeth D. Hawkes , Irina I. Gout ,
Ahmed N. El-Amir , James E. Neffendorf

PII: S2211-0348(18)30324-9
DOI: <https://doi.org/10.1016/j.msard.2018.09.012>
Reference: MSARD 967



To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 25 February 2018
Revised date: 4 September 2018
Accepted date: 11 September 2018

Please cite this article as: Abigail E. Kaye , Elizabeth D. Hawkes , Irina I. Gout , Ahmed N. El-Amir , James E. Neffendorf , Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma, *Multiple Sclerosis and Related Disorders* (2018), doi: <https://doi.org/10.1016/j.msard.2018.09.012>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- There is no strong evidence to suggest a causal relationship between natalizumab and development of melanoma, nor transformation of primary naevi.
- The role of $\alpha_4\beta_1$ integrin in the metastatic cascade is likely complex and requires further investigation to determine the consequences of its blockade in relation to development of melanoma.
- It is advised that clinicians consider available disease modifying agents other than natalizumab in patients with a history of melanoma.

Download English Version:

<https://daneshyari.com/en/article/10212477>

Download Persian Version:

<https://daneshyari.com/article/10212477>

[Daneshyari.com](https://daneshyari.com)